Dose-escalation study of rivaroxaban (BAY 59–7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement - Eriksson, BI; Borris, LC; Dahl, OE (Thromb Res, 2007)
doi:10.1016/j.thromres.2006.12.025.